iBio, Inc. (NYSEAMERICAN: IBIO) is a biotechnology company that develops and commercializes plant-based expression technologies for the production of biologic therapeutics, vaccines and other protein-based products. The company’s proprietary IBIOprime platform leverages transient expression in Nicotiana benthamiana plants to rapidly generate proteins and antibodies for human and animal health applications. iBio offers an integrated suite of services encompassing early-stage research, process development, and commercial-scale manufacturing in a USDA-licensed bioprocessing facility.
Founded in 2005 and headquartered in College Station, Texas, iBio evolved from early work in agricultural biotechnology to focus on biopharmaceutical manufacturing. Over the years, the company has refined its platform to enable accelerated timelines—often measured in weeks rather than months—for key steps such as gene expression, protein purification, and scale-up. This agile approach has attracted partnerships with academic institutions, government agencies and biopharmaceutical firms seeking rapid-response capabilities for emerging infectious diseases and specialty therapeutics.
iBio’s product portfolio includes vaccine candidates against influenza, RSV, Zika and other viruses, as well as monoclonal antibodies and fusion proteins targeting oncology and rare diseases. In addition to in-house pipeline programs, the company provides contract development and manufacturing (CDMO) services to clients in North America, Europe and Asia, offering end-to-end solutions from vector design to fill-and-finish packaging. Its modular, cGMP-compliant facility supports both clinical and commercial production, with flexible capacity to accommodate single-use bioreactors and downstream purification trains.
Under the leadership of Chief Executive Officer Martin Stoll and a management team with deep expertise in bioprocess engineering, regulatory affairs and commercial operations, iBio continues to advance its platform and expand collaborative partnerships. The company maintains research collaborations with major academic centers and participates in government programs aimed at pandemic preparedness. Through its innovative plant-based approach, iBio seeks to deliver cost-effective manufacturing solutions and novel therapies to global markets.
AI Generated. May Contain Errors.
Free IBIO Stock Alerts